Ohr Pharmaceutical

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that develops gene silencing therapies with its synthetic antisense oligonucleotides. It also provides a platform that focuses on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy, and Familial Parkinson's Disease, among others.

Ohr Pharmaceutical announced that all of its proposals relating to its proposed merger with Neubase Therapeutics were approved by Ohr's stockholders at a special meeting held today.

News for Ohr Pharmaceutical Stock (OHRP)